Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.47 -1.0%	$187.07	$163.81 ▼ $218.66	$334.49B	0.48	6.30 million shs	1.25 million shs
EBS Emergent Biosolutions	$7.10 -2.5%	$6.55	$4.02 ▼ $15.10	$385.12M	2.09	1.66 million shs	287,112 shs
IRWD Ironwood Pharmaceuticals	$0.79 +0.4%	$0.68	$0.53 ▼ $7.11	$128.49M	0.3	2.54 million shs	312,619 shs
LXRX Lexicon Pharmaceuticals	$1.29 -4.8%	$0.79	$0.28 ▼ $2.45	$464.52M	1.13	6.86 million shs	2.46 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.38%	-1.90%	+3.15%	+10.70%	+9.11%
EBS Emergent Biosolutions	+4.27%	-0.61%	+16.84%	+57.85%	-39.44%
IRWD Ironwood Pharmaceuticals	+6.91%	+1.92%	+24.61%	+9.08%	-88.40%
LXRX Lexicon Pharmaceuticals	+4.65%	+19.47%	+87.34%	+164.81%	-36.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7932 of 5 stars	3.4	3.0	3.3	3.9	3.2	1.7	1.3
EBS Emergent Biosolutions	4.1562 of 5 stars	3.5	1.0	0.0	4.6	1.4	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.3757 of 5 stars	3.1	4.0	0.0	3.4	2.9	0.8	1.9
LXRX Lexicon Pharmaceuticals	2.5813 of 5 stars	3.2	3.0	0.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.52% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	102.02% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	502.43% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	185.34% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, LXRX, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/22/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$210.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.94	$14.85 per share	12.76	$1.90 per share	99.72
EBS Emergent Biosolutions	$1.04B	0.37	$1.95 per share	3.64	$8.91 per share	0.80
IRWD Ironwood Pharmaceuticals	$351.41M	0.37	$0.05 per share	14.95	($1.88) per share	-0.42
LXRX Lexicon Pharmaceuticals	$31.08M	14.95	N/A	N/A	$0.40 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.58	13.55	1.26	7.31%	412.03%	13.11%	7/31/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.43	N/A	-13.63%	-0.52%	-0.17%	8/6/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	3.18	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)

Latest IRWD, ABBV, LXRX, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IRWD Ironwood Pharmaceuticals	-$0.02	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	N/A	279.15%	53 Years
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest IRWD, ABBV, LXRX, and EBS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
EBS Emergent Biosolutions	1.20	6.32	3.51
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
EBS Emergent Biosolutions	78.40%
IRWD Ironwood Pharmaceuticals	N/A
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
EBS Emergent Biosolutions	1.20%
IRWD Ironwood Pharmaceuticals	12.70%
LXRX Lexicon Pharmaceuticals	13.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable

IRWD, ABBV, LXRX, and EBS Headlines

Recent News About These Companies

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

5 hours ago | globenewswire.com

Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.67

July 13, 2025 | americanbankingnews.com

Lexicon Pharmaceuticals, Inc. (LXRX) - Yahoo Finance

July 12, 2025 | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by Brokerages

July 10, 2025 | marketbeat.com

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension

July 3, 2025 | tipranks.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?

July 2, 2025 | marketbeat.com

While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership

June 30, 2025 | finance.yahoo.com

LXRX - Lexicon Pharmaceuticals Inc Price vs Fair Value - Morningstar

June 26, 2025 | morningstar.comM

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC Wainwright

June 24, 2025 | marketbeat.com

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock

June 24, 2025 | investing.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average - Here's What Happened

June 24, 2025 | marketbeat.com

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 23, 2025 | globenewswire.com

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 18, 2025 | globenewswire.com

Lexicon Pharmaceuticals surges 67% following InvestingPro's Fair Value signal

June 8, 2025 | investing.com

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

May 21, 2025 | insidermonkey.com

Lexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy Rating

May 20, 2025 | tipranks.com

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 19, 2025 | globenewswire.com

Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 19, 2025 | finanznachrichten.de

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 17, 2025 | finance.yahoo.com

Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 11.08%

May 15, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD, ABBV, LXRX, and EBS Company Descriptions

AbbVie NYSE:ABBV

$189.46 -1.94 (-1.01%)

As of 12:37 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Emergent Biosolutions NYSE:EBS

$7.10 -0.19 (-2.54%)

As of 12:36 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.79 +0.00 (+0.40%)

As of 12:35 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.28 -0.07 (-4.81%)

As of 12:36 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time